Literature DB >> 18240953

Normalization of B cell counts and subpopulations after antiretroviral therapy in chronic HIV disease.

Susan Moir1, Angela Malaspina, Jason Ho, Wei Wang, Angela C Dipoto, Marie A O'Shea, Gregg Roby, Joann M Mican, Shyam Kottilil, Tae-Wook Chun, Michael A Proschan, Anthony S Fauci.   

Abstract

BACKGROUND: Untreated human immunodeficiency virus (HIV) disease leads to abnormalities in all major lymphocyte populations, including CD4(+) T cells, CD8(+) T cells, and B cells. However, little is known regarding the effect of antiretroviral therapy (ART)-induced decrease in HIV viremia on B cell numbers and subpopulations.
METHODS: We conducted a longitudinal study to evaluate changes in B cell numbers and subpopulations that occur during the course of 12 months of effective ART in a group of individuals with chronic HIV infection.
RESULTS: ART-induced decrease in HIV viremia was associated with a significant increase in B cell counts, similar to increases in CD4(+) T cell counts yet distinct from the lack of increase in CD8(+) T cells. The increase in B cell counts was accompanied by a significant decrease in the frequency of apoptosis-prone B cell subpopulations, namely mature activated and immature transitional B cells, which are overrepresented in untreated HIV disease. The increase in B cell counts was reflected by a significant increase in naive and resting memory B cells, both of which represent populations that are essential for generating adequate humoral immunity.
CONCLUSIONS: Normalization of B cell counts and subpopulations may help to explain the improvement in humoral immunity reported to occur after an ART-induced decrease in HIV viremia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18240953     DOI: 10.1086/526789

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  76 in total

1.  HIV-1 single-stranded RNA induces CXCL13 secretion in human monocytes via TLR7 activation and plasmacytoid dendritic cell-derived type I IFN.

Authors:  Kristen W Cohen; Anne-Sophie Dugast; Galit Alter; M Juliana McElrath; Leonidas Stamatatos
Journal:  J Immunol       Date:  2015-02-09       Impact factor: 5.422

2.  Innate immune defects correlate with failure of antibody responses to H1N1/09 vaccine in HIV-infected patients.

Authors:  Suresh Pallikkuth; Sudheesh Pilakka Kanthikeel; Sandra Y Silva; Margaret Fischl; Rajendra Pahwa; Savita Pahwa
Journal:  J Allergy Clin Immunol       Date:  2011-07-12       Impact factor: 10.793

3.  Evolution of broadly cross-reactive HIV-1-neutralizing activity: therapy-associated decline, positive association with detectable viremia, and partial restoration of B-cell subpopulations.

Authors:  Carolina B Ferreira; Alberto Merino-Mansilla; Anuska Llano; Ignacio Pérez; Isabel Crespo; Laia Llinas; Felipe Garcia; Jose M Gatell; Eloisa Yuste; Victor Sanchez-Merino
Journal:  J Virol       Date:  2013-09-04       Impact factor: 5.103

Review 4.  How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development?

Authors:  Per Johan Klasse; Rogier W Sanders; Andrea Cerutti; John P Moore
Journal:  AIDS Res Hum Retroviruses       Date:  2011-05-20       Impact factor: 2.205

5.  Broadly cross-neutralizing antibodies in HIV-1 patients with undetectable viremia.

Authors:  M Medina-Ramírez; V Sánchez-Merino; S Sánchez-Palomino; A Merino-Mansilla; C B Ferreira; I Pérez; N González; A Alvarez; J M Alcocer-González; F García; J M Gatell; J Alcamí; E Yuste
Journal:  J Virol       Date:  2011-04-06       Impact factor: 5.103

Review 6.  Premature B-cell senescence as a consequence of chronic immune activation.

Authors:  Paolo Palma; Stefano Rinaldi; Nicola Cotugno; Veronica Santilli; Savita Pahwa; Paolo Rossi; Alberto Cagigi
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 7.  Immune reconstitution and vaccination outcome in HIV-1 infected children: present knowledge and future directions.

Authors:  Alberto Cagigi; Nicola Cotugno; Carlo Giaquinto; Luciana Nicolosi; Stefania Bernardi; Paolo Rossi; Iyadh Douagi; Paolo Palma
Journal:  Hum Vaccin Immunother       Date:  2012-08-21       Impact factor: 3.452

8.  B-lymphocyte dysfunction in chronic HIV-1 infection does not prevent cross-clade neutralization breadth.

Authors:  Saikat Boliar; Megan K Murphy; T Cameron Tran; Diane G Carnathan; Wendy S Armstrong; Guido Silvestri; Cynthia A Derdeyn
Journal:  J Virol       Date:  2012-05-23       Impact factor: 5.103

9.  Antiretroviral therapy restores age-dependent loss of resting memory B cells in young HIV-infected Zambian children.

Authors:  Kaitlin Rainwater-Lovett; Hope C Nkamba; Mwnagelwa Mubiana-Mbewe; Carolyn B Moore; Joseph B Margolick; William J Moss
Journal:  J Acquir Immune Defic Syndr       Date:  2014-04-15       Impact factor: 3.731

10.  Characterization of plasmablasts in the blood of HIV-infected viremic individuals: evidence for nonspecific immune activation.

Authors:  Clarisa M Buckner; Susan Moir; Jason Ho; Wei Wang; Jacqueline G Posada; Lela Kardava; Emily K Funk; Amy K Nelson; Yuxing Li; Tae-Wook Chun; Anthony S Fauci
Journal:  J Virol       Date:  2013-03-13       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.